The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site

Journal of Biological Chemistry

Volumn 288, Issue 33, 2013, Pages 24223-24233

  Mizanur, Rahman M ^a   Frasca, Verna ^b   Swaminathan, Subramanyam ^c   Bavari, Sina ^a   Webb, Robert ^a   Smith, Leonard A ^d   Ahmed, S Ashraf ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b GE Healthcare Life Sciences   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d Office of the Chief Scientist   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

BOTULINUM NEUROTOXINS; C-TERMINAL PEPTIDES; CATALYTIC DOMAINS; CATALYTIC PROTEINS; PRODUCT RELEASE; PROTEOLYTIC ACTIVITIES; STOICHIOMETRIC CONCENTRATION; UNIQUE FEATURES;

PROTEINS;

BOTULINUM TOXIN A; LIGHT CHAIN B PEPTIDE; LIGHT CHAIN C1 PEPTIDE; LIGHT CHAIN D PEPTIDE; LIGHT CHAIN E PEPTIDE; LIGHT CHAIN F PEPTIDE; NEUROPEPTIDE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVE SITE; INHIBITION KINETICS; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN STABILITY; RESIDUE ANALYSIS; SEQUENCE ANALYSIS; STOICHIOMETRY;

EID: 84882431363     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.451286     Document Type: Article

References (48)

1. Sugahara, M., Asada, Y., Shimizu, K., Yamamoto, H., Lokanath, N. K., Mizutani, H., Bagautdinov, B., Matsuura, Y., Taketa, M., Kageyama, Y., Ono, N., Morikawa, Y., Tanaka, Y., Shimada, H., Nakamoto, T., Sugahara M, Yamamoto, M., and Kunishima, N. (2008) High-throughput crystallization-to-structure pipeline at RIKEN SPring-8 Center. J. Struct. Funct. Genomics 9, 21-28
2. Liu, Z. J., Tempel, W., Ng, J. D., Lin, D., Shah, A. K., Chen, L., Horanyi, P. S., Habel, J. E., Kataeva, I. A., Xu, H., Yang, H., Chang, J. C., Huang, L., Chang, S. H., Zhou, W., Lee, D., Praissman, J. L., Zhang, H., Newton, M. G., Rose, J. P., Richardson, J. S., Richardson, D. C., and Wang, B. C. (2005) The high-throughput protein-to-structure pipeline at SECSG. Acta Crystallogr. D Biol. Crystallogr. 61, 679-684
3. Nilsson, L. O., Edalat, M., Pettersson, P. L., and Mannervik, B. (2002) Aromatic residues in the C-terminal region of glutathione transferase A1-1 influence rate-determining steps in the catalytic mechanism. Biochim. Biophys. Acta 1598, 199-205
4. Peng, D., Ma, L. H., Ogura, H., Yang, E. C., Zhang, X., Yoshida, T., and La Mar, G. N. (2010) 1H NMR study of the influence of mutation on the interaction of the C-terminus with the active site in heme oxygenase from Neisseria meningitidis: implications for product release. Biochemistry 49, 5832-5840
5. Angelucci, F., Sayed, A. A., Williams, D. L., Boumis, G., Brunori, M., Dimastrogiovanni, D., Miele, A. E., Pauly, F., and Bellelli, A. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284, 28977-28985
6. Kucera, N. J., Hodsdon, M. E., and Wolin, S. L. (2011) An intrinsically disordered C terminus allows the La protein to assist the biogenesis of diverse noncoding RNA precursors. Proc. Natl. Acad. Sci. U.S.A. 108, 1308-1313
7. MacDonald, J. A., Ishida, H., Butler, E. I., Ulke-Lemée, A., Chappellaz, M., Tulk, S. E., Chik, J. K., and Vogel, H. J. (2012) Intrinsically disordered N-terminus of calponin homology-associated smooth muscle protein (CHASM) interacts with the calponin homology domain to enable tropomyosin binding. Biochemistry 51, 2694-2705
8. Bartels, T., Ahlstrom, L. S., Leftin, A., Kamp, F., Haass, C., Brown, M. F., and Beyer, K. (2010) The N-terminus of the intrinsically disordered protein-synuclein triggers membrane binding and helix folding. Biophys. J. 99, 2116-2124
9. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R., and Stevens, R. C. (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898-902
10. DasGupta, B. R., and Dekleva, M. L. (1990) Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and around the nicking site. Biochimie 72, 661-664
11. Krieglstein, K. G., DasGupta, B. R., and Henschen, A. H. (1994) Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Protein Chem. 13, 49-57
12. Kumaran, D., Rawat, R., Ludivico, M. L., Ahmed, S. A., and Swaminathan, S. (2008) Structure-and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J. Biol. Chem. 283, 18883-18891
13. Silvaggi, N. R., Wilson, D., Tzipori, S., and Allen, K. N. (2008) Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 47, 5736-5745
14. Mizanur, R. M., Gorbet, J., Swaminathan, S., and Ahmed, S. A. (2012) Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium. IJBMB 3, 313-321
15. Breidenbach, M. A., and Brunger, A. T. (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929
16. Ahmed, S. A., Olson, M. A., Ludivico, M. L., Gilsdorf, J., and Smith, L. A. (2008) Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J. 27, 151-162
17. Kumaran, D., Rawat, R., Ahmed, S. A., and Swaminathan, S. (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog. 4, e1000165
18. Baldwin, M. R., Bradshaw, M., Johnson, E. A., and Barbieri, J. T. (2004) The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr. Purif. 37, 187-195
19. Eubanks, L. M., Hixon, M. S., Jin, W., Hong, S., Clancy, C. M., Tepp, W. H., Baldwin, M. R., Malizio, C. J., Goodnough, M. C., Barbieri, J. T., Johnson, E. A., Boger, D. L., Dickerson, T. J., and Janda, K. D. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. U.S.A. 104, 2602-2607
20. Burnett, J. C., Ruthel, G., Stegmann, C. M., Panchal, R. G., Nguyen, T. L., Hermone, A. R., Stafford, R. G., Lane, D. J., Kenny, T. A., McGrath, C. F., Wipf, P., Stahl, A. M., Schmidt, J. J., Gussio, R., Brunger, A. T., and Bavari, S. (2007) Inhibition of metalloprotease botulinum serotypeAfrom a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 282, 5004-5014
21. Burnett, J. C., Wang, C., Nuss, J. E., Nguyen, T. L., Hermone, A. R., Schmidt, J. J., Gussio, R., Wipf, P., and Bavari, S. (2009) Pharmacophoreguided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorg. Med. Chem. Lett. 19, 5811-5813
22. Molles, B. E., Collins, E. K., Levit, M. B., Sweeny, R. E., Zottola, M. A., Sunil-Datta, S., Tucker, W., Zeytin, F. N., Ruge, D., Oyler, G., Ahmed, S. A., Smith, L. A., Barbieri, J. T., Janda, K. D., O'Malley, S., and Adler, M., (2010) in Program and Abstract Book: 40th Inter-institute Botulinum Research Coordinating Committee Meeting, Interventions II Section, Dekatur, Atlanta, GA, November 1-5, (Maslanka, S. E., ed) Centers for Disease Control and Prevention, Atlanta, GA
23. Ahmed, S. A., Byrne, M. P., Jensen, M., Hines, H. B., Brueggemann, E., and Smith, L. A. (2001) Enzymatic autocatalysis of botulinum A neurotoxin light chain. J. Protein Chem. 20, 221-231
24. Dasgupta, B. R., Antharavally, B. S., Tepp, W., and Evenson, M. L. (2005) Botulinum neurotoxin types A, B, and E: fragmentations by autoproteolysis and other mechanisms including by O-phenanthroline-dithiothreitol, and association of the dinucleotides NAD/NADH with the heavy chain of the three neurotoxins. Protein J. 24, 337-368
25. Ahmed, S. A., McPhie, P., and Smith, L. A. (2003) Autocatalytically fragmented light chain of botulinum A neurotoxin is enzymatically active. Biochemistry 42, 12539-12549
26. Jensen, M. J., Smith, T. J., Ahmed, S. A., and Smith, L. A. (2003) Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon 41, 691-701
27. Gilsdorf, J., Gul, N., and Smith, L. A. (2006) Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr. Purif. 46, 256-267
28. Segelke, B., Knapp, M., Kadkhodayan, S., Balhorn, R., and Rupp, B. (2004) Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity. Proc. Natl. Acad. Sci. U.S.A. 101, 6888-6893
29. Rawat, R., Ashraf Ahmed, S., and Swaminathan, S. (2008) High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficientHPLCassay to monitor its proteolytic activity. Protein Expr. Purif. 60, 165-169
30. Hale, M., Oyler, G., Swaminathan, S., and Ahmed, S. A. (2011) Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem. 286, 1802-1811
31. Foran, P., Shone, C. C., and Dolly, J. O. (1994) Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 33, 15365-15374
32. Rowe, B., Schmidt, J. J., Smith, L. A., and Ahmed, S. A. (2010) Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity. Anal. Biochem. 396, 188-193
33. Silvaggi, N. R., Boldt, G. E., Hixon, M. S., Kennedy, J. P., Tzipori, S., Janda, K. D., and Allen, K. N. (2007) Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem. Biol. 14, 533-542
34. Thompson, A. A., Jiao, G. S., Kim, S., Thai, A., Cregar-Hernandez, L., Margosiak, S. A., Johnson, A. T., Han, G. W., O'Malley, S., and Stevens, R. C. (2011) Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. Biochemistry 50, 4019-4028
35. Chen, S., and Barbieri, J. T. (2006) Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem. 281, 10906-10911
36. Lacy, D. B., and Stevens, R. C. (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291, 1091-1104
37. Velazquez-Campoy, A., Leavitt, S. A., and Freire, E. (2004) Characterization of protein-protein interactions by isothermal titration calorimetry. Methods Mol. Biol. 261, 35-54
38. Toth, S. I., Smith, L. A., and Ahmed, S. A. (2009) Extreme sensitivity of botulinum neurotoxin domains towards mild agitation. J. Pharm. Sci. 98, 3302-3311
39. Ahmed, S. A., Ludivico, M. L., and Smith, L. A. (2004) Factors affecting autocatalysis of botulinum A neurotoxin light chain. Protein J. 23, 445-451
40. Mathews, C. K., and van Holde, K. E. (1990) in Biochemistry, 1st Ed., pp. 339-377 The Benjamin/Cummings Publishing Co, Inc., Menlo Park CA
41. Ahmed, S. A., Hyde, C. C., Thomas, G., and Miles, E. W. (1987) Microcrystals of tryptophan synthase α2α2 complex from Salmonella typhimurium are catalytically active. Biochemistry 26, 5492-5498
42. Ahmed, S. A., Martin, B., and Miles, E. W. (1986)-Elimination of indole from L-tryptophan catalyzed by bacterial tryptophan synthase: a comparison between reactions catalyzed by tryptophanase and tryptophan synthase. Biochemistry 25, 4233-4240
43. Weber-Ban, E., Hur, O., Bagwell, C., Banik, U., Yang, L. H., Miles, E. W., and Dunn, M. F. (2001) Investigation of allosteric linkages in the regulation of tryptophan synthase: the roles of salt bridges and monovalent cations probed by site-directed mutation, optical spectroscopy, and kinetics. Biochemistry 40, 3497-3511
44. Henkel, J. S., Jacobson, M., Tepp, W., Pier, C., Johnson, E. A., and Barbieri, J. T. (2009) Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48, 2522-2528
45. Montecucco, C., and Schiavo, G. (1995) Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 28, 423-472
46. Silhár, P., Lardy, M. A., Hixon, M. S., Shoemaker, C. B., Barbieri, J. T., Struss, A. K., Lively, J. M., Javor, S., and Janda, K. D. (2013) The C-terminus of botulinum A protease has profound and unanticipated kinetic consequences upon the catalytic cleft. ACS Med. Chem. Lett. 4, 283-287
47. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38
48. Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193